A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

about

Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.

P2860

Q49963125-7064AA96-5FD6-49BA-90CD-C98BBA2A3230

P2860

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

Item

http://www.wikidata.org/entity/Q38623340

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

@en

type

Item

label

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

@en

prefLabel

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

@en

P1476

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

@en

P2093

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Litao Zhang

http://www.w3.org/2001/XMLSchema#string

Qingxia Zhan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Systematic reviews in health care: Assessing the quality of controlled clinical trials

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.

Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis.

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

P304

431-437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.1080/21645515.2015.1081322

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2015-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26528924

http://www.w3.org/2001/XMLSchema#string

P921

P932

5049748

http://www.w3.org/2001/XMLSchema#string

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

about

P2860

P2860

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932